Literature DB >> 18177475

Chiral separation of racemate CPU86017, an anti-arrhythmic agent, produces stereoisomers possessing favourable ion channel blockade and less alpha-adrenoceptor antagonism.

Na Li1, Lin Yang, De-Zai Dai, Qiu-Juan Wang, Yin Dai.   

Abstract

1. CPU86017 is an effective anti-arrhythmic agent of the Class III complex that has two chiral centres, 7N and 13aC. As a promising anti-arrhythmic agent, the blockade on I(Kr), I(Ks) and calcium influx may be modulated to be mild, moderate and potent, with less a-adrenoceptor blockade. In order to improve activity at ion channels, four stereoisomers, namely SS ((+)-7S,13aS-CPU86017), SR ((-)-7S,13aR-CPU86017), RR ((-)-7R,13aR-CPU86017) and RS ((+)-7R,13aS-CPU86017), have been separated. In the present study, the effects of these four isomers on I(Kr) and I(Ks), calcium channels and a-adrenoceptors were compared with the effects of the racemate CPU86017. 2. In the present study, I(Kr) and I(Ks) were measured as tail currents (I(Kr.tail) and I(Ks.tail), respectively) using the whole-cell patch-clamp technique. Antagonism of receptor-operated calcium channels and voltage-dependent calcium channels (VDC) in vascular smooth muscle by CPU86017 and the four isomers were tested as suppression of phenylephrine- or KCl-induced contractions of aortic rings, respectively. 3. For I(Kr.tail) inhibition, the IC(50) of SS, SR, RR, RS and CPU86017 was 2.86 +/- 1.20, 39.4 +/- 8.5, 3.48 +/- 0.80, 7.65 +/- 1.50 and 12.5 +/- 7.8 x 10(-9) mol/L, respectively; for I(Ks.tail) inhibition IC(50) values were 16.9 +/- 4.0, 20.0 +/- 2.1, 99.1 +/- 5.9, 160 +/- 81 and 65.0 +/- 4.7 x 10(-9) mol/L, respectively. The SR isomer showed balanced blockade of I(Kr) and I(Ks) that was associated with a loss of a-adrenoceptor antagonism but enhanced VDC blockade. 4. Configuration of 13aC critically determines I(Kr) blockade and the Ca(2+) antagonism of the isomers of CPU86017. The SR isomer exhibits mild blockade of I(Kr), moderately enhanced blockade of I(Ks) and Ca(2+) influx and less a-adrenoceptor antagonism compared with the racemate and may be promising as an anti-arrhythmic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18177475     DOI: 10.1111/j.1440-1681.2007.04854.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

1.  Hypoxia/oxidative stress alters the pharmacokinetics of CPU86017-RS through mitochondrial dysfunction and NADPH oxidase activation.

Authors:  Jie Gao; Xuan-sheng Ding; Yu-mao Zhang; De-zai Dai; Mei Liu; Can Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2013-10-14       Impact factor: 6.150

2.  CPU86017-RS attenuate hypoxia-induced testicular dysfunction in mice by normalizing androgen biosynthesis genes and pro-inflammatory cytokines.

Authors:  Guo-lin Zhang; Feng Yu; De-zai Dai; Yu-si Cheng; Can Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

3.  Raisanberine protected pulmonary arterial rings and cardiac myocytes of rats against hypoxia injury by suppressing NADPH oxidase and calcium influx.

Authors:  Jie Gao; Yi-qun Tang; De-zai Dai; Yu-si Cheng; Guo-lin Zhang; Can Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

4.  CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation.

Authors:  Na Li; De-Zai Dai; Yin Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

Review 5.  Promising Antioxidative Effect of Berberine in Cardiovascular Diseases.

Authors:  Na An; Guoxia Zhang; Yingjian Li; Chao Yuan; Fan Yang; Lijing Zhang; Yonghong Gao; Yanwei Xing
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.